EA201201081A1 - Производные гетарил[1,8]нафтиридина - Google Patents

Производные гетарил[1,8]нафтиридина

Info

Publication number
EA201201081A1
EA201201081A1 EA201201081A EA201201081A EA201201081A1 EA 201201081 A1 EA201201081 A1 EA 201201081A1 EA 201201081 A EA201201081 A EA 201201081A EA 201201081 A EA201201081 A EA 201201081A EA 201201081 A1 EA201201081 A1 EA 201201081A1
Authority
EA
Eurasian Patent Office
Prior art keywords
highlights
note
hetaryl
naphthyridine
atp
Prior art date
Application number
EA201201081A
Other languages
English (en)
Russian (ru)
Inventor
Альфред Йончик
Дитер Дорш
Гюнтер Хёльцеманн
Кристиане Амендт
Франк Ценке
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201201081A1 publication Critical patent/EA201201081A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA201201081A 2010-02-05 2010-12-17 Производные гетарил[1,8]нафтиридина EA201201081A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10001251 2010-02-05
PCT/EP2010/007743 WO2011095196A1 (en) 2010-02-05 2010-12-17 Hetaryl-[1,8]naphthyridine derivatives

Publications (1)

Publication Number Publication Date
EA201201081A1 true EA201201081A1 (ru) 2013-03-29

Family

ID=43531801

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201081A EA201201081A1 (ru) 2010-02-05 2010-12-17 Производные гетарил[1,8]нафтиридина

Country Status (14)

Country Link
US (2) US8614226B2 (https=)
EP (1) EP2531500B1 (https=)
JP (1) JP5675850B2 (https=)
KR (1) KR20120124469A (https=)
CN (1) CN102741249B (https=)
AU (1) AU2010344973B2 (https=)
BR (1) BR112012018954A2 (https=)
CA (1) CA2789021C (https=)
EA (1) EA201201081A1 (https=)
ES (1) ES2667049T3 (https=)
MX (1) MX2012008550A (https=)
SG (1) SG182803A1 (https=)
WO (1) WO2011095196A1 (https=)
ZA (1) ZA201206630B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2528441T3 (es) * 2010-02-22 2015-02-10 Merck Patent Gmbh Hetarilaminonaftiridinas
JP5826261B2 (ja) * 2010-06-28 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 癌に対する使用のためのキナーゼ阻害剤としての2,4−ジアリール置換[1,8]ナフチリジン
US8575424B2 (en) * 2010-07-07 2013-11-05 Dow Agrosciences, Llc. Production of functionalized linear DNA cassette and quantum dot/nanoparticle mediated delivery in plants
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
EP2903615B1 (en) 2012-10-05 2021-04-07 Merck Sharp & Dohme Corp. 5-pyridin-3-yl-2,3-dihydro-1h-indole derivatives as aldosterone synthase (cyp11b2) inhibitors for the treatment of hypertension
KR20150072412A (ko) 2012-10-05 2015-06-29 리겔 파마슈티칼스, 인크. Gdf-8 억제제
MA38287B1 (fr) 2013-01-23 2018-08-31 Astrazeneca Ab Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
CN103113369A (zh) * 2013-03-21 2013-05-22 云南大学 一种具有抗肿瘤活性的苯并[b][1,8]-萘啶-2-(1H)-亚胺衍生物及合成方法
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 1,7-萘啶衍生物
JP6496731B2 (ja) 2013-11-27 2019-04-03 シグナルケム・ライフサイエンシーズ・コーポレイションSignalchem Lifesciences Corporation Tamファミリーキナーゼ阻害剤としてのアミノピリジン誘導体
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AU2015206652A1 (en) 2014-01-14 2016-08-04 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN106536507B (zh) * 2014-04-08 2020-04-07 里格尔药品股份有限公司 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
AU2021205893A1 (en) 2020-01-08 2022-06-23 Synthis Therapeutics, Inc. ALK5 inhibitor conjugates and uses thereof
WO2023244788A1 (en) * 2022-06-17 2023-12-21 Neuron23, Inc. Kinase modulators and methods of use thereof
CN121712526A (zh) 2023-06-13 2026-03-20 辛瑟斯治疗股份有限公司 抗cd5抗体及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR207555A1 (es) 1972-12-04 1976-10-15 Procedimiento para preparar aril-6-piperazinocarboniloxi-5 oxo-7 tetrahidro-2,3,6,7 ditiino(1,4)(2,3-c)pirroles
IT1245712B (it) * 1991-04-09 1994-10-14 Boehringer Mannheim Italia Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree
US5994367A (en) * 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
ATE491689T1 (de) 1997-10-27 2011-01-15 Neurosearch As Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY
GB0117060D0 (en) * 2001-07-12 2001-09-05 Merck Sharp & Dohme Therapeutic agents
EP1511738A4 (en) * 2002-05-17 2007-05-09 Scios Inc TREATMENT OF FIBROPROLIFERATIVE DISEASES USING TGF BETA INHIBITORS
ES2305744T3 (es) * 2003-03-12 2008-11-01 Millennium Pharmaceuticals, Inc. Derivados de quinazolina como inhibidores e tgf-beta.
WO2005080377A1 (ja) * 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
ES2528674T3 (es) * 2005-02-17 2015-02-11 Astellas Pharma Inc. Piperidina y carboxilatos de piperacina como inhibidores de FAAH
DE602006018354D1 (de) 2005-12-05 2010-12-30 Pfizer Prod Inc Verfahren zur behandlung von abnormalem zellwachstum
JP4751856B2 (ja) 2007-07-03 2011-08-17 本田技研工業株式会社 車体側部構造
DE102007049451A1 (de) 2007-10-16 2009-04-23 Merck Patent Gmbh 5-Cyano-thienopyridine
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
WO2009099982A1 (en) 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
DE102008017853A1 (de) 2008-04-09 2009-10-15 Merck Patent Gmbh Thienopyrimidine
EA201001687A1 (ru) 2008-04-29 2011-06-30 Новартис Аг Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 )
EP2445902A2 (en) * 2009-06-25 2012-05-02 Amgen, Inc Heterocyclic compounds and their uses as inhibitors of pi3k activity
ES2528441T3 (es) * 2010-02-22 2015-02-10 Merck Patent Gmbh Hetarilaminonaftiridinas
JP5826261B2 (ja) * 2010-06-28 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 癌に対する使用のためのキナーゼ阻害剤としての2,4−ジアリール置換[1,8]ナフチリジン

Also Published As

Publication number Publication date
US8912216B2 (en) 2014-12-16
BR112012018954A2 (pt) 2016-04-12
KR20120124469A (ko) 2012-11-13
AU2010344973A1 (en) 2012-09-20
US20120295902A1 (en) 2012-11-22
MX2012008550A (es) 2012-09-07
CA2789021C (en) 2018-02-06
SG182803A1 (en) 2012-09-27
EP2531500B1 (en) 2018-01-24
AU2010344973B2 (en) 2016-06-16
JP2013518832A (ja) 2013-05-23
CA2789021A1 (en) 2011-08-11
JP5675850B2 (ja) 2015-02-25
CN102741249A (zh) 2012-10-17
CN102741249B (zh) 2015-11-25
EP2531500A1 (en) 2012-12-12
ZA201206630B (en) 2013-05-29
US20140038960A1 (en) 2014-02-06
WO2011095196A1 (en) 2011-08-11
US8614226B2 (en) 2013-12-24
ES2667049T3 (es) 2018-05-09

Similar Documents

Publication Publication Date Title
EA201201081A1 (ru) Производные гетарил[1,8]нафтиридина
EA201201170A1 (ru) Гетариламинонафтиридины
EA201000094A1 (ru) Производные пиримидинил-пиридазинона
EA201200653A1 (ru) Гетариламинохинолины
EA201300873A1 (ru) Производные 7-азаиндола
EA201100966A1 (ru) Производные пиридазинона
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
EA201200119A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201001005A1 (ru) Производные 2-бензилпиридазинона в качестве ингибиторов мет киназы
EA201100125A1 (ru) Производные пирролопиридинилпиримидин-2-иламина
EA201101399A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201000004A1 (ru) Производные 6-(пирролопиридинил)пиримидин-2-иламина и их применение для лечения злокачественного новообразования и спида
EA201001648A1 (ru) Производные пиридазинона
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
EA201401212A1 (ru) Производные пирролотриазинона
EA201200951A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
EA200901601A1 (ru) Производные пиридазинона
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
EA201290880A1 (ru) Новые соединения - ингибиторы фермента
UA108105C2 (ru) Азотсодержащие гетероарильные соединения
EA201100334A1 (ru) Бициклические производные триазола для лечения опухолей
EA201790882A1 (ru) Способы и композиции для терапии рака печени
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201390803A1 (ru) Ингибиторы бромодомена и их применение